The section above analyzed the framework for prognostic CRC biomarkers, focusing on traditional markers such as CEA and CA 19-9, along with novel biomarkers such as CTCs, KRAS/NRAS/BRAF mutations, MSI/MMR, and ctDNA. The gene discussed is KRAS; the disease is colorectal carcinoma.